The association for types of CVD varied by cancer subtype: a history of CAD and a history of hypertension were associated with lower anthracycline use in luminal and HER2 + cancers, but not in triple negative cancer (0.89, 0.76–1.03); a history of stroke and heart failure was significantly associated with lower anthracycline use in all subtypes; and a history of VTE had no impact on anthracycline use for any subtype. This evidence concerns the gene ERBB2 and cancer.